{
    "guideline_identifier": "PIIS2059702924014339.txt",
    "cancer_focus": {
        "primary_cancer": "Rare Neuroendocrine Neoplasms and Related Cancers",
        "related_syndrome_or_condition": ""
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Local/Locoregional Disease",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "UKP NENs - NETs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Radical resection ± exploration for occult primary (e.g., mesenteric mass)",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "UKP NENs - NECs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Neoadjuvant platinum-etoposide ± radiotherapy",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "GU/Gy NENs - NETs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Conservative surgery if feasible; adjuvant RT for G3/R1–R2 resection",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "V C"
                },
                {
                    "clinical_context": "GU/Gy NENs - NECs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Multimodal therapy (surgery + chemoradiotherapy)",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "HN NENs - Larynx/sinonasal NETs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Radical surgery + neck dissection; adjuvant RT for G2/non-R0 resection",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "HN NENs - NECs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Chemoradiotherapy ± surgery",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Parathyroid Carcinoma (PC)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "En bloc resection + ipsilateral thyroidectomy/central node dissection; adjuvant RT for R1–R2/N+",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "V C"
                },
                {
                    "clinical_context": "Intrathyroid Thymic Carcinoma (ITC)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Thyroidectomy/lobectomy + neck dissection; avoid adjuvant RT unless advanced",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV D"
                }
            ]
        },
        {
            "staging_criteria": "Advanced/Metastatic Disease",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "NENs (UKP/GU/Gy/HN) - G1/G2 NETs SSTR+",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Somatostatin analogs (SSAs)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "SSTR",
                            "status": "Positive",
                            "testing_guidance": "SSTR-PET (68Ga-DOTA-SSA) for diagnosis/staging"
                        }
                    ],
                    "esmo_evidence_level": "IV B"
                },
                {
                    "clinical_context": "NENs (UKP/GU/Gy/HN) - SSTR−/progressive NETs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Everolimus or antiangiogenic multikinase inhibitors (sunitinib)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "SSTR",
                            "status": "Negative",
                            "testing_guidance": "SSTR-PET (68Ga-DOTA-SSA) for diagnosis/staging"
                        }
                    ],
                    "esmo_evidence_level": "IV B"
                },
                {
                    "clinical_context": "NENs (UKP/GU/Gy/HN) - G3 NETs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Everolimus, alkylating agents (temozolomide ± capecitabine), or oxaliplatin-based chemo",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "NENs (UKP/GU/Gy/HN) - NECs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum-etoposide",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV A"
                },
                {
                    "clinical_context": "NENs (UKP/GU/Gy/HN) - NECs progressing after first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "FOLFIRI/FOLFOX",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "V B"
                },
                {
                    "clinical_context": "NENs (UKP/GU/Gy/HN) - SSTR+ NETs progressing on SSAs",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "PRRT",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "SSTR",
                            "status": "Positive",
                            "testing_guidance": "SSTR-PET (68Ga-DOTA-SSA) for diagnosis/staging"
                        }
                    ],
                    "esmo_evidence_level": "IV B"
                },
                {
                    "clinical_context": "Functional Carcinoid Syndrome",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "SSAs → telotristat ethyl/IFN-α/PRRT",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Functional Cushing Syndrome",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Metyrapone/ketoconazole → bilateral adrenalectomy",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Parathyroid Carcinoma (PC) - Hypercalcemia",
                    "recommendation_type": "Symptom Management",
                    "recommendation_content": "Cinacalcet, hydration, zoledronic acid/denosumab",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II A"
                },
                {
                    "clinical_context": "Parathyroid Carcinoma (PC) - Systemic Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Antiangiogenics (sorafenib) or alkylating agents (dacarbazine)",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "V B/C"
                },
                {
                    "clinical_context": "Intrathyroid Thymic Carcinoma (ITC)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Cisplatin-based chemo (doxorubicin/cyclophosphamide or etoposide)",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "V B"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Biomarkers guide diagnosis (IHC for TTF-1/CDX-2), treatment selection (SSTR for PRRT/SSAs; TMB for immunotherapy), therapy response prediction (MGMT for alkylating agents), and syndrome monitoring (chromogranin A/5-HIAA)."
    }
}